Home / Community / News / News

News

01/28/2016 - 7:35am

The use of anesthesia raises special risks to DM patients, which include heightened sensitivity to sedatives and analgesics. Serious complications are most common in the post-anesthesia period when risk of aspiration and other complications are increased. 

MDF has published two versions of its 2016 Anesthesia Guidelines:

  • Click here for a handy, one-page summary of the anesthesia guidelines to share with your clinician and anesthesiologist. 
  • Click here for the complete "Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient".

New to DM? For here for more information.

 

01/14/2016 - 12:32pm

Word came from the FDA on January 14th that it would not approve the new drug application for "Kendrisa,"  Biomarin's antisense-oligo based drug for Duchenne muscular dystrophy.

12/10/2015 - 4:18am

Established by the MD CARE Act in 2001, the Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee composed of representatives from major government agencies relevant to muscular dystrophy and a selection of “public” members representing patients and disease advocacy associations. The Commi

12/02/2015 - 11:36am

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

12/02/2015 - 4:55am

Kathie Bishop, Ph.D.
Tioga Pharmaceuticals
San Diego, California

Member, Scientific Advisory Committee (SAC)
Myotonic Dystrophy Foundation (MDF)

Partners

© Myotonic Dystrophy Foundation. All rights reserved.